Dr. Conlon is the CEO of Nuchido, a new company that is set to launch soon.
she claims NAD+ precursors long term is pointless as the body adjusts after some time and the precursors eventually have no effect.
They have a cocktail called NCD201 which they claim solves this problem and continues to work to raise NAD levels long term. Results of testing will theoretically be released later this year.
i know nothing about this other than whats presented here, but thought it was interesting
https://www.leafscie...nichola-conlon/
However, Nuchido does not believe that NAD+ precursor supplementation alone will deliver robust long-term benefits in humans. One reason for this is because NAD+ precursors are costly when the dosage is scaled up from mouse to human body weights. Another reason is that while increasing the input to a biological system may result in increased output in the short term, it is likely to lead to a decline of efficacy in the long term as the system readjusts to the new input level.
To address this, the company is using systems pharmacology to design therapeutic “cocktails” that contain multiple therapies to be delivered at once. This cocktail contains NAD+ precursors along with other compounds that act on the enzymes that produce and destroy NAD+; the ultimate aim is to increase the NAD+ in the system while also increasing and maintaining the activity of the machinery that produces NAD+.
The company created its first therapeutic cocktail called NCD201, which was designed for oral consumption. Working with a university laboratory, they tested its effect on a single 57-year-old male as an initial proof of concept for the approach.